Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069311
Filing Date
2025-05-12
Accepted
2025-05-12 16:33:46
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nmra-20250331.htm   iXBRL 10-Q 2469493
2 EX-31.1 nmra-ex31_1.htm EX-31.1 19486
3 EX-31.2 nmra-ex31_2.htm EX-31.2 19744
4 EX-32.1 nmra-ex32_1.htm EX-32.1 11631
5 EX-32.2 nmra-ex32_2.htm EX-32.2 11848
6 GRAPHIC img236770017_0.jpg GRAPHIC 1968724
  Complete submission text file 0000950170-25-069311.txt   13952560

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20250331.xsd EX-101.SCH 1260330
67 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20250331_htm.xml XML 1566700
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41802 | Film No.: 25935417
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)